DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Röllig C, Serve H, Hüttmann A. et al. Study Alliance Leukaemia.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol 2015;
16 (16) 1691-1699
We do not assume any responsibility for the contents of the web pages of other providers.